- Nuclein, LLC, an Austin, Texas-based medical device company, closed a $14m Series B funding round
- The round was led by Trinity Private Equity Group, a Southlake, Texas-based private equity firm
- The company also intends to use the funds to to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis
- Nuclein also provides a device that runs real-time PCR, does not require technical expertise to operate, and delivers battery-powered, sample-to-answer results from saliva in under one hour
- Nuclein currently employs approximately 30 scientists, engineers, and other professionals
- It is seeking to immediately hire additional molecular biologists, engineers, and manufacturing staff to support its growth
